BioLife Products to Showcase Patented Oral Peptide Delivery Technology at London Life Sciences Week 2026
BioLife Products Limited will present its patented oral peptide delivery technology and recent intellectual property developments at London Life Sciences Week 2026, highlighting its efforts to address longstanding challenges associated with the oral administration of peptide-based medicines. The company’s participation will include a presentation at the LSX Investival Showcase, where it plans to outline the scientific development of its technology, preclinical findings and potential applications across the expanding peptide therapeutics market.
The presentation is scheduled for Monday, November 16, 2026, from 3:15 to 3:30 p.m. GMT, at Old Billingsgate in London. Former US Ambassador James P. Cain, Strategic Advisor to the Chairman and Founder, will lead the presentation alongside Ludivine Delattre, who is responsible for Business and Corporate Relations at BioLife.
The company intends to use the event to introduce investors, industry participants and other stakeholders to its proprietary approach to oral peptide delivery. The presentation will also highlight the research underlying the platform, the progress of its intellectual property portfolio and the potential opportunities for applying the technology to peptide-based therapeutics.
Addressing the Challenges of Oral Peptide Administration
Peptide medicines have become an increasingly important area of pharmaceutical development, with applications across metabolic disorders and other therapeutic fields. However, developing effective oral formulations for peptide drugs remains challenging because these molecules can be vulnerable to degradation in the gastrointestinal tract and may have difficulty crossing the intestinal barrier.
Many peptide therapies are currently administered through injections, which can create practical challenges for patients who require long-term treatment. An effective oral delivery approach could potentially provide an alternative administration option, depending on the therapeutic candidate, clinical performance and regulatory requirements.
BioLife Products is developing a delivery platform intended to address these challenges through a proprietary dissolvable effervescent tablet. The technology is designed to generate a buffered solution that helps protect peptide molecules during gastrointestinal transit and supports their potential absorption into systemic circulation.
The platform is based on more than 35 years of pharmaceutical effervescence expertise and approximately two decades of oral peptide research conducted by the company’s founder and inventor, Dr. Farid Bennis.
By combining established effervescence formulation knowledge with research focused on peptide delivery, BioLife aims to develop a formulation approach that could expand the possibilities for administering peptide therapeutics orally. The company’s work focuses on creating conditions that may help preserve peptide stability during passage through the gastrointestinal environment while supporting systemic exposure following administration.
The technology is intended to address a central formulation problem in peptide drug development: how to protect sensitive molecules from degradation and facilitate their delivery without relying on conventional injectable administration.
Effervescent Formulation Designed to Support Peptide Protection
BioLife’s delivery approach uses a dissolvable tablet that forms a buffered solution when introduced to liquid. According to the company, this formulation is designed to help protect peptide therapeutics as they pass through the gastrointestinal tract.
The effervescent format is central to the platform’s development strategy. Rather than relying solely on conventional oral dosage forms, BioLife is investigating how a controlled formulation environment can support the delivery of peptide molecules.
The company’s research draws on its long-standing experience in pharmaceutical effervescence, a formulation technology used to produce rapidly dissolving preparations. BioLife has combined this expertise with research into the specific barriers that affect oral peptide administration.
Peptides can present formulation difficulties because their molecular structures may be susceptible to enzymatic breakdown and other conditions encountered during digestion. In addition, the absorption of many peptide molecules through the intestinal lining can be limited. These challenges have historically restricted the development of oral versions of several peptide-based medicines.
BioLife’s platform is being developed to address these barriers through a formulation strategy that combines buffering and effervescence. The company believes this approach could provide a basis for investigating oral delivery across different peptide therapeutics.
However, the performance of the technology must be established separately for each therapeutic candidate. Peptides can differ in their chemical properties, stability, absorption characteristics and therapeutic requirements. Consequently, findings involving one molecule cannot automatically be applied to all other peptide medicines.
Preclinical Semaglutide Findings Provide Proof of Concept
BioLife reported that preclinical studies have demonstrated measurable systemic semaglutide exposure following oral administration using its technology. The company described these findings as in vivo proof of concept for its delivery approach.
The observation of systemic exposure is an important research milestone because it provides evidence that semaglutide administered through the oral formulation can reach systemic circulation under the conditions examined in the preclinical studies.
Semaglutide is a peptide-based therapeutic associated with the broader development of glucagon-like peptide-1 (GLP-1) receptor agonists. The growing use and development of GLP-1-based medicines have increased interest in alternative delivery approaches that could potentially improve treatment convenience and expand formulation options.
For BioLife, the preclinical findings provide an initial scientific basis for further investigation of its technology in relation to semaglutide and other peptide medicines.
The company also pointed to earlier human clinical research involving oral insulin formulations. Together, the preclinical semaglutide observations and previous human research provide a foundation for continued scientific evaluation of the platform.
The findings should nevertheless be viewed in the context of the development stage. Measurable systemic exposure in preclinical studies does not establish clinical efficacy, safety, therapeutic equivalence or successful commercial application in humans. Further research and validation will be required to determine whether the formulation can consistently deliver specific peptide medicines at clinically meaningful levels.
BioLife’s presentation at London Life Sciences Week is expected to provide an opportunity to explain the scientific work completed to date and discuss the potential direction of its development programme.
Intellectual Property Portfolio Covers Multiple GLP-1 Receptor Agonists
Alongside its formulation research, BioLife is advancing an intellectual property portfolio intended to protect key elements of its oral peptide delivery technology.
The company has secured granted patents in the United States and France, while additional international patent filings are progressing. This intellectual property position is an important component of BioLife’s strategy as it seeks to develop its technology and explore potential applications across the peptide therapeutics sector.
According to the company, its granted U.S. patent includes claims covering multiple GLP-1 receptor agonists. The named molecules include:
- Semaglutide
- Liraglutide
- Dulaglutide
- Albiglutide
- Exenatide
- Lixisenatide
The U.S. patent protection is stated to extend into 2042. The inclusion of multiple GLP-1 receptor agonists within the patent claims provides a foundation for the company’s efforts to protect its technology across a range of peptide-based medicines within this therapeutic category.
The breadth of the intellectual property portfolio could be relevant as pharmaceutical companies continue to explore formulation strategies for peptide medicines. However, patent claims and granted protection do not, by themselves, establish that every named molecule has been successfully formulated or demonstrated to achieve clinically effective oral delivery using the platform.
BioLife’s ongoing work will therefore involve further scientific validation, alongside continued development of its patent position in relevant international markets.
Founder Highlights Longstanding Research into Oral Peptide Delivery
Dr. Farid Bennis, Founder of BioLife Products, emphasized the growing importance of drug-delivery innovation as peptide therapeutics continue to evolve.
“The rapid evolution of peptide medicines continues to create opportunities for innovation in drug delivery,” said Dr. Farid Bennis, Founder of BioLife. “Our work reflects many years of research into the challenges of oral peptide delivery. London Life Sciences Week provides an important opportunity to share our progress and explore the potential of this approach with those advancing the next generation of peptide therapeutics.”
His comments reflect the company’s focus on developing an alternative formulation strategy for a class of medicines that has traditionally faced significant oral-delivery limitations.
The technology’s development combines Dr. Bennis’s two decades of research into oral peptide formulations with BioLife’s broader experience in pharmaceutical effervescence. The company is seeking to translate this research into a platform that could potentially be applied to multiple peptide-based therapies.
The opportunity to present at the LSX Investival Showcase also gives BioLife a platform to communicate its scientific progress to investors and industry stakeholders. London Life Sciences Week brings together participants from across the life sciences ecosystem, creating opportunities for companies to discuss research programmes, business strategies, intellectual property and potential partnerships.
LSX Investival Showcase to Highlight Development Opportunities
BioLife’s presentation at the LSX Investival Showcase will take place at Old Billingsgate on November 16, 2026, between 3:15 and 3:30 p.m. GMT.
Former US Ambassador James P. Cain, Strategic Advisor to the Chairman and Founder, will lead the presentation with Ludivine Delattre, Business and Corporate Relations. The session will focus on the scientific journey behind BioLife’s oral peptide delivery technology and its potential applications.
The presentation is expected to cover the company’s formulation approach, the research supporting its development, preclinical observations involving oral semaglutide exposure and the progress of its patent portfolio.
For BioLife, engagement with the life sciences investment community is an opportunity to explain how its technology could fit into the broader development landscape for peptide medicines. Interest in oral peptide delivery has grown alongside advances in peptide therapeutics, particularly as pharmaceutical developers consider ways to improve administration options for patients.
The company’s strategy is based on the possibility that a formulation platform capable of protecting peptides and supporting systemic delivery could have applications beyond a single drug candidate. Its U.S. patent claims covering several GLP-1 receptor agonists reflect this broader intellectual property positioning.
Nevertheless, the extent of the platform’s eventual application will depend on additional research, candidate-specific validation and the ability to demonstrate appropriate safety, exposure and therapeutic performance.
Further Validation Will Be Important for Future Development
BioLife’s announcement highlights three central elements of its development programme: its effervescent oral delivery technology, the scientific findings generated through preclinical and earlier human research, and its expanding intellectual property position.
The reported systemic semaglutide exposure following oral administration provides an initial in vivo indication that the platform warrants further investigation. Earlier human clinical research involving oral insulin formulations adds to the scientific background supporting the company’s approach. The granted patents in the United States and France, together with additional international filings, provide an intellectual property framework for future development.
However, further validation will be necessary before the technology’s potential can be established across additional peptide medicines. Each candidate will require appropriate evaluation to determine whether the formulation can protect the molecule, support absorption and achieve exposure levels suitable for its intended therapeutic use.
As peptide-based treatments continue to attract pharmaceutical research and investment, drug-delivery technologies that address the limitations of conventional administration could become an important area of development. BioLife is positioning its platform within this evolving field by combining decades of effervescence expertise with focused research into oral peptide formulations.
Through its participation in London Life Sciences Week 2026, the company plans to present its progress to the international life sciences community, explain the scientific rationale behind its approach and highlight the potential applications supported by its current research and patent portfolio.
About the Technology
BioLife’s patented effervescent peptide delivery technology uses a dissolvable tablet to create a buffered solution designed to help protect peptide medicines during gastrointestinal transit and support systemic delivery. Preclinical studies have demonstrated measurable systemic semaglutide exposure following oral administration.
The development programme builds on nearly 20 years of research, including human clinical studies with oral insulin formulations and work with Charles River Laboratories, SGS, Eurofins/Amatsi and Cephac. The technology is in development and is not approved for the treatment of any disease.
About BioLife
BioLife develops oral delivery technologies for peptide medicines, combining expertise in pharmaceutical effervescence, formulation science and oral peptide research. The company’s technology portfolio and related patent estate have been independently developed and are wholly owned.